Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07116499) titled 'A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of K-645 in the Treatment of Multiple Migraine Attacks' on Aug. 7.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).
Primary Sponsor: Kallyope Inc.
Condition:
Acute Migraine
Intervention:
Drug: Placebo
Drug: K-645 dose level 1
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: August 7, 2025
Target Sample Size: 120
Countries of Recruitment:
United States
To know more, vis...